To see the other types of publications on this topic, follow the link: Cystic fibrosis Gene therapy.

Books on the topic 'Cystic fibrosis Gene therapy'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 books for your research on the topic 'Cystic fibrosis Gene therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse books on a wide variety of disciplines and organise your bibliography correctly.

1

Love, Cynthia B. Genetic testing for cystic fibrosis: January 1989 through February 1997 : 1224 citations. Bethesda, Md. (8600 Rockville Pike, Bethesda 20894): U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health, National Library of Medicine, Reference Section, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

United States. Congress. Senate. Committee on Small Business. Research on childhood diseases by entrepreneurs: Hearing before the Committee on Small Business, United States Senate, One Hundred Third Congress, second session ... Thursday, May 26, 1994. Washington: U.S. G.P.O., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

United States. Congress. Senate. Committee on Small Business. Research on childhood diseases by entrepreneurs: Hearing before the Committee on Small Business, United States Senate, One Hundred Third Congress, second session ... Thursday, May 26, 1994. Washington: U.S. G.P.O., 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Skypala, Isabel. Eating well with cystic fibrosis. Bromley: Cystic Fibrosis Trust, 1994.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tsui, Lap-Chee, Giovanni Romeo, Rainer Greger, and Sergio Gorini, eds. The Identification of the CF (Cystic Fibrosis) Gene. Boston, MA: Springer US, 1991. http://dx.doi.org/10.1007/978-1-4684-5934-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Ferguson, Kate. The physical treatment of cystic fibrosis. Bromley: Cystic Fibrosis Trust, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mofford, K. A. Preclinical studies in DNA/liposome gene transfer for cystic fibrosis. Oxford: Oxford Brookes University, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

MacDonald, Anita. Eating well with cystic fibrosis: A guide for children and parents. Bromley: Cystic Fibrosis Trust, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

1932-, Elston Robert C., ed. Multipoint mapping and linkage based upon affected pedigree members: Genetic Analysis Workshop 6, proceedings of a workshop held at Gulf Park, Long Beach, Mississippi, October 10-12, 1988. New York: Liss, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Duguay, François. Use of the Xenopus oocyte as a potential expression system for the cystic fibrosis gene. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
11

Li, Xiaobin. Characterization of multiple copies of a DNA segment containing cystic fibrosis transmembrane conductance regulator gene exon 9 in the human genome. Ottawa: National Library of Canada, 1999.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
12

Association, American Diabetes, ed. American Diabetes Association guide to medical nutrition therapy for diabetes. 2nd ed. Alexandria, Va: American Diabetes Association, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
13

Lee, Benjamin Haeyul. Gene delivery to human sweat glands: A model for cystic fibrosis gene therapy. 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
14

Ryan, Jeanne. Charisma. Simon & Schuster, Limited, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
15

Charisma. 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
16

Sayer, John A., and Roslyn J. Simms. Nephronophthisis. Edited by Neil Turner. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0317_update_001.

Full text
Abstract:
Nephronophthisis (NPHP) is a clinically heterogeneous autosomal recessive cystic kidney disease and the leading genetic cause of end-stage renal failure in children and young adults. Whilst enlarged dysplastic cystic kidneys are associated with infantile NPHP, more typically renal ultrasound reveals normal kidney size and corticomedullary cysts in a child with polyuria and secondary enuresis. Extrarenal manifestations occur in 10–15% including retinal degeneration, cerebellar vermis hypoplasia and liver fibrosis, requiring referral to other specialists. Mutations in 18 genes have been identified to cause NPHP, but a genetic diagnosis still cannot be found in many patients. NPHP is classified as a ciliopathy because of the localization of the protein products of the associated genes. Currently there is no specific therapy for NPHP.
APA, Harvard, Vancouver, ISO, and other styles
17

National Heart, Lung, and Blood Institute, ed. Facts about cystic fibrosis. [Bethesda, Md: National Institutes of Health, National Heart, Lung, and Blood Institute, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
18

Thursfield, Rebecca, Chris Orchard, Rosanna Featherstone, and Jane C. Davies. Future treatments. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780198702948.003.0013.

Full text
Abstract:
There are only a relatively limited armoury of drugs, the majority of which are aimed at downstream symptoms of cystic fibrosis. Therapies targeting the basic defect in CF as well as continued availability of more conventional drugs are required. Progress in gene therapy has been limited by the significant barriers to gene transfer of the CF lung, but the UK is hosting a large repeated dose trial of nebulized non-viral gene therapy designed around clinically meaningful outcomes. The UK CF Gene Therapy Consortium is also seeking to develop a promising modified lentiviral approach, although this is some years off. Perhaps the exciting development of recent decades has come from small molecule CFTR modulators, driven by an understanding of basic pathophysiological mechanisms. Ivacaftor is the first drug to be licensed, having proved itself highly clinically efficacious in patients with the class-3 gating mutation G551D. The trial pipeline seeks to expand indications for this and to explore the potential of Phe508del correctors. Finally, a number of anti-inflammatory and anti-infective strategies are being pursued. The emerging global problem of antibiotic resistance is leading to exciting alternatives such as biofilm disruption and bacteriophage to be explored.
APA, Harvard, Vancouver, ISO, and other styles
19

Beattie, R. Mark, Anil Dhawan, and John W.L. Puntis. Cystic fibrosis. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569862.003.0021.

Full text
Abstract:
Gastrointestinal manifestations 156Management of gastrointestinal symptoms in children with CF 158Nutrition in CF 158Nutritional management 159Vitamins 160The incidence of cystic fibrosis (CF) is around 1 in 2500. Cases are diagnosed as a consequence of population screening or high-risk screening, or following presentation with clinical symptoms typical of the disorder. The basic defect is in the CFTR (cystic fibrosis transmembrane conductance regulator) protein which codes for a cyclic adenosine monophosphate-regulated chloride transporter in epithelial cells of exocrine organs. This is involved in salt and water balance across epithelial surfaces. The gene is on chromosome 7. There are multiple known mutations, the most common being ...
APA, Harvard, Vancouver, ISO, and other styles
20

Lap-Chee, Tsui, ed. The Identification of the CF (cystic fibrosis) gene: Recent progress and new research strategies. New York: Plenum Press, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
21

Cystic Fibrosis: Medical Care. Lippincott Williams & Wilkins, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
22

(Editor), Lap-Chee Tsui, Giovanni Romeo (Editor), Rainer Greger (Editor), and Sergio Gorini (Editor), eds. The Identification of the CF (Cystic Fibrosis) Gene: Recent Progress and New Research Strategies (Advances in Experimental Medicine and Biology). Springer, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
23

Watson, Ronald Ross. Diet and Exercise in Cystic Fibrosis. Elsevier Science & Technology Books, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
24

Molecular Basis and Gene Therapies of Cystic Fibrosis. MDPI, 2020. http://dx.doi.org/10.3390/books978-3-03943-684-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Beattie, R. Mark, Anil Dhawan, and John W.L. Puntis. Cystic fibrosis-associated liver disease. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780198569862.003.0022.

Full text
Abstract:
Pathophysiology 162Clinical features 162Diagnosis 163Management 164Cystic fibrosis (CF) is an autosomal recessive disease resulting from mutations in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) (see Chapter 21). CFTR functions as a transmembrane chloride channel in the apical membrane of most secretory epithelia and the disease thus affects lungs, pancreas, exocrine glands, gut, and liver. In CF-associated liver disease the biliary tract is most commonly involved in a spectrum from asymptomatic to biliary cirrhosis. The liver disease runs from mild and subclinical to severe cirrhosis and portal hypertension. Clinical disease is seen in 4–6% of cases, but there are biochemical abnormalities in 20–50%. At autopsy, fibrosis is present in 20% and steatosis in 50%....
APA, Harvard, Vancouver, ISO, and other styles
26

US GOVERNMENT. Cystic Fibrosis and DNA Tests: Implications of Carrier Screening. Office of Technology Assessment, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
27

United States. Congress. Office of Technology Assessment., ed. Cystic fibrosis and DNA tests: Implications of carrier screening. Washington, DC: Congress of the U.S., Office of Technology Assessment, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
28

Cystic Fibrosis: A Trilogy of Biochemistry, Physiology, and Therapy. Cold Spring Harbor Laboratory Press, 2013.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
29

Carsten, Schultz, ed. Defects of secretion in cystic fibrosis. New York: Springer, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
30

1945-, Orenstein David M., and Stern Robert C. 1938-, eds. Treatment of the hospitalized cystic fibrosis patient. New York: M. Dekker, 1998.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
31

United States. Congress. Office of Technology Assessment., ed. Cystic fibrosis and DNA tests: Implications of carrier screening : summary. Washington, D.C: Congress of the U.S., Office of Technology Assessment, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
32

Kriemler, Susi. Exercise, physical activity, and cystic fibrosis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199232482.003.0033.

Full text
Abstract:
Cystic fibrosis (CF) is the most common genetic autosomal recessive disease of the Caucasian race, generally leading to death in early adulthood.1 The frequency of the gene carrier (heterozygote) is 1:20–25 in Caucasian populations, 1:2000 in African-Americans, and practically non-existent in Asian populations. The disease occurs in about 1 in every 2500 life births of the white population. Mean survival has risen from 8.4 years in 1969 to 32 years in 2000 due to improvements in treatment. The genetic defect causes a pathological electrolyte transport through the cell membranes by a defective chloride channel membrane transport protein [cystic fibrosis transmembrane conductance regulator (CFTR)]. With respect to the function, this affects mainly the exocrine glands of secretory cells, sinuses, lungs, pancreas, liver, and the reproductive tract of the human body leading to a highly viscous, water-depleted secretion. The secretion cannot leave the glands and in consequence causes local inflammation and destruction of various organs. The main symptoms include chronic inflammatory pulmonary disease with a progressive loss of lung function, exocrine and sometimes endocrine pancreas insufficiency, and an excessive salt loss through the sweat glands.1 A summary of the signs and symptoms of CF will be given with a special emphasis on the effect of exercise performance and capacity.
APA, Harvard, Vancouver, ISO, and other styles
33

Heather, Nicky. Nutritional management of cystic fibrosis. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198759928.003.0024.

Full text
Abstract:
This chapter covers the nutritional management of cystic fibrosis. This includes discussion of the risk factors for malnutrition, assessment of nutritional status, assessment of nutritional requirements, and practical management. The chapter includes a section on pancreatic enzyme replacement therapy.
APA, Harvard, Vancouver, ISO, and other styles
34

Cystic Fibrosis Pulmonary Infections: Lessons from Around the World. Birkhäuser, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
35

A, Bauernfeind, Marks Melvin I, and Strandvik B, eds. Cystic fibrosis pulmonary infections: Lessons from around the world. Basel: Birkhauser Verlag, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
36

United States. Congress. Office of Technology Assessment., ed. Genetic counseling and cystic fibrosis carrier screening: Results of a survey. Washington, DC: Congress of the U.S., Office of Technology Assessment, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
37

US GOVERNMENT. Genetic Counseling and Cystic Fibrosis Carrier Screening: Results of a Survey (Background Paper). Office of Technology Assessment, 1992.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
38

Cuppens, Harry. Genetic Studies of the Cystic Fibrosis Transmembrane Conductance Regulator Gene in Belgian Cf Patients. Coronet Books Inc, 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
39

Multipoint mapping and linkage based upon affected pedigree members: Genetic Analysis Workshop 6, proceedings of a workshop held at Gulf Park, Long Beach, ... in clinical and biological research). Liss, 1989.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
40

Cystic Fibrosis Pulmonary Infections: Lessons from Around the World (Respiratory Pharmacology and Pharmacotherapy). Birkhauser, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
41

(Editor), Adolf Bauernfeind, Melvin I. Marks (Editor), and Brigitta Strandvik (Editor), eds. Cystic Fibrosis Pulmonary Infections: Lessons from Around the World (Respiratory Pharmacology and Pharmacotherapy). Birkhauser, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
42

Cole, Desmond. CBD Oil for Cystic Fibrosis: Alternative Therapy for the Management and Treatment of Liver Fibrosis Using CBD Oil. Independently Published, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
43

Pitt, Tyrone. Antibiotic Resistance in Systic Fibrosis - an Emerging Crisis? (International Congress and Symposium). Edited by Tyrone Pitt. Royal Society of Medicine Press, 2003.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
44

Burmer, Karl. CBD Oil for Cystic Fibrosis: Effective Therapy for Severe Damage in the Lung and Digestive System. Independently Published, 2019.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
45

Strategies for Pharmacokinetic Optimization of Continuous Infusion Therapy of Ceftazidime and Aztreonam in Patients with Cystic Fibrosis. CIP-DATA, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
46

Slack, Jonathan. 3. Mutations and gene variants. Oxford University Press, 2014. http://dx.doi.org/10.1093/actrade/9780199676507.003.0003.

Full text
Abstract:
All gene variants originate as mutations. Most variants in the genome of any given individual are not new mutations but have been inherited from previous generations. ‘Mutations and gene variants’ shows that mutations can occur in any cell of the body, but in order to be inherited they must occur in the DNA of the reproductive cells. There are numerous genetic diseases caused by a single mutation in one gene, and the examples considered here are cystic fibrosis, haemophilia, achondroplasia, and Holt-Oram Syndrome. In such cases, the inheritance of the abnormal gene variant follows simple Mendelian rules. The origin of cancer is explained as a combination of mutations occurring in a single cell of the body. Inherited gene variants predisposing to cancer do so because they reduce the number of new mutations required.
APA, Harvard, Vancouver, ISO, and other styles
47

Koch, Ch. Inhalation Therapy: Roche and Genentech Symposium European Cystic Fibrosis Conference, Paris, June 1994 (Respiration, Vol 62, Suppl 1). S. Karger AG (Switzerland), 1995.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
48

M, Geddes Duncan, ed. Colistin: New insights and practical issues : proceedings of a symposium held at the British Library, London, UK, on 27 January 2004. London: Royal Society of Medicine Press, 2004.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
49

Recipes for the Specific Carbohydrate Diet: The Grain-Free, Dairy-Free, Sugar-Free Solution to IBD, Celiac Disease, Autism, Cystic Fibrosis, and other ... Conditions (Healthy Living Cookbooks). Fair Winds, 2008.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
50

Michels, Virginia V. Genetics. Oxford University Press, 2012. http://dx.doi.org/10.1093/med/9780199755691.003.0276.

Full text
Abstract:
Genetic factors play a role in the development of many types of human disease. Genetic determinants may be chromosome abnormalities (Down syndrome, Kleinfelter syndrome, Turner syndrome), single gene defects (dilated and hypertrophic cardiomyopathies, Ehlers-Danlos syndrome, Marfan syndrome, neurofibromatosis, tuberous sclerosis, Gaucher disease, cystic fibrosis, sickle cell disease), mitochondrial mutations (MELAS, MERRF, Kearns-Sayre syndrome), or epigenetic or multifactorial factors. Genetics testing methods are also reviewed.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography